NCT00966966View on ClinicalTrials.gov

Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Healthy
Interventions
DRUG

SAM-531 and gemfibrozil

2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days

Trial Locations (1)

3584 CJ

Pfizer Investigational Site, Utrecht

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00966966 - Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered | Biotech Hunter | Biotech Hunter